BioSpace News Archive

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the third quarter ended September 30, 2021 and provided an overview of recent corporate developments.

Amarin Corporation plc announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following upcoming investor conferences.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conferences.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, reported its financial results for the quarter ended September 30, 2021.

Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases.

PacBio announced that its executives will be speaking at the following investor conferences.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended September 30, 2021, and provided a business update.

Disc Medicine, today announced that the company and its collaborators at Boston Children’s Hospital have been selected to give an oral presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Beyond Air, Inc. announced financial results for its first fiscal quarter ended September 30, 2021.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2021.